476060.KQ KOE
Onconic Therapeutics
1W: +3.8%
1M: -12.7%
3M: +14.8%
YTD: -8.8%
1Y: -37.8%
₩15,710.00 ($11.69)
-210.00 (-1.32%)
Weekly Expected Move ±6.2%
₩13769
₩14739
₩15710
₩16681
₩17651
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Balance Sheet Trends
Total Assets
$75.7B
+24.3% ▲
4Y CAGR: +40.5%
Total Liabilities
$3.7B
-25.1% ▼
4Y CAGR: -39.5%
Shareholders Equity
$72.0B
+28.6% ▲
Cash & Investments
$52.7B
+22.6% ▲
4Y CAGR: +29.3%
Total Debt
$126M
-59.2% ▼
4Y CAGR: -9.7%
Net Debt
-$46.9B
-9.9% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $18.9B | $27.3B | $30.1B | $43.0B | $47.0B |
| Short-Term Investments | $0 | $0 | $0 | $0 | $5.7B |
| Cash & ST Investments | $18.9B | $27.3B | $30.1B | $43.0B | $52.7B |
| Net Receivables | $174M | $842M | $367M | $7.6B | $10.9B |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $0 | $350 | $0 | -$270 | $0 |
| Total Current Assets | $19.0B | $28.2B | $30.8B | $52.1B | $63.8B |
| Property, Plant & Equip. | $264M | $2.6B | $3.6B | $3.3B | $3.1B |
| Goodwill & Intangibles | $5M | $4M | $2M | $1M | $98K |
| Long-Term Investments | $0 | $0 | $0 | $138M | $7M |
| Other Non-Current Assets | $111M | $113M | $118M | $0 | $2M |
| Total Non-Current Assets | $379M | $2.7B | $6.8B | $8.8B | $11.9B |
| Total Assets | $19.4B | $30.9B | $37.5B | $60.9B | $75.7B |
| — Liabilities — | |||||
| Accounts Payable | $0 | $0 | $0 | $709M | $2.7B |
| Short-Term Debt | $0 | $0 | $0 | $189M | $81M |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $22M | $26.3B | $55.0B | -$80M | $850M |
| Total Current Liabilities | $528M | $26.6B | $57.0B | $4.8B | $3.6B |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | $26.8B | $26.3B | $29M | $10M | $0 |
| Total Non-Current Liabilities | $26.9B | $26.3B | $228M | $129M | $45M |
| Total Liabilities | $27.4B | $52.8B | $57.2B | $4.9B | $3.7B |
| — Equity — | |||||
| Common Stock | $2.9B | $2.9B | $2.9B | $5.4B | $22.2B |
| Retained Earnings | -$18.3B | -$32.7B | -$31.0B | -$39.1B | $26.7B |
| Accumulated OCI | $0 | $0 | $0 | $2.3B | $537M |
| Total Stockholders Equity | -$8.0B | -$21.9B | -$19.7B | $56.0B | $72.0B |
| Total Liabilities & Equity | $19.4B | $30.9B | $37.5B | $60.9B | $75.7B |
| — Key Metrics — | |||||
| Total Debt | $189M | $51M | $354M | $308M | $126M |
| Net Debt | -$18.7B | -$27.3B | -$29.7B | -$42.7B | -$46.9B |
| Total Investments | $0 | $0 | $0 | $138M | $5.7B |